We are researching if a monthly GLP-1 RA study medicine can help improve symptoms of knee osteoarthritis (OA) in people living with overweight or obesity.
People living with overweight or obesity are more likely to experience knee osteoarthritis (OA). Losing just 10% of body weight has been shown to help reduce knee pain and improve knee function and is often the first treatment doctors recommend.1-3
If you decide to join the Vesper-OA 1 study, your health and knee OA symptoms will be carefully monitored. You will also receive guidance on diet, exercise, and lifestyle from a team of weight loss specialists and be given a variety of tools to support you every step of the way.
Who may participate
Each clinical trial has its own guidelines for who can participate, called eligibility criteria. Some of the eligibility criteria to participate in this clinical trial include:
Knee osteoarthritis
Have been diagnosed with knee osteoarthritis with knee pain for at least 12 weeks
Overweight or obesity
Body mass index (BMI) of 27 or higher
Diabetes
Have not been diagnosed with diabetes
Age
18+ years
Additional requirements apply
The study team will discuss other requirements with you and determine if you are eligible to participate in this clinical trial.
What to expect
Before you decide to join this clinical trial, the study team will perform some screening tests to see if the study is a good fit for you.
If you meet all the requirements, your participation will last about 63 weeks with in- person or telehealth visits approximately every 4 weeks.
During the Treatment Period, you will be randomly assigned (like pulling a number out of a hat) to receive either the study medicine or a placebo. The placebo looks like the study medicine but does not have any active ingredients in it. You will reach your target monthly dose through gradual dose escalation.
Both the study medicine and the placebo will be given as an injection under the skin. You, or a caregiver, will be instructed on how to give the injections at home.
After you finish the Treatment Period, you will have 2 additional follow-up visits.
Length of study treatment
52 weeks
Number of study visits
About 14 in-person visits and 4 telehealth visits
Study-related costs
No cost to participate, and health insurance is not required
About the study medicine
The study medicine is a GLP-1 RA (glucagon-like peptide-1 receptor agonist). It mimics the effects of a hormone in your body called GLP-1 that helps control your appetite and blood sugar. Along with a healthy diet and exercise, it may help people lose weight by:
- Increasing a feeling of fullness after eating
- Slowing down digestion
- Reducing appetite
- Regulating blood sugar levels
The study medicine is designed to be long acting, which may allow people to achieve their weight loss goals with only 1 dose per month once they reach their target dose

Together we can make a difference
For many people, finding solutions to manage their weight and knee OA symptoms can be a challenge. We are committed to advancing research that may expand weight management treatment options for people living with knee OA and overweight or obesity.
Many factors—including age, overall health, lifestyle, and individual differences—can affect weight management and how a person responds to potential treatment. That’s why it’s important for this clinical trial to include people from a wide range of backgrounds. This will help researchers better understand the study medicine and how it may work for different people.
Your participation and commitment could make a difference for people looking for treatment options to help manage their weight and improve their knee OA symptoms.

Osteoarthritis (OA) is a common joint disease that happens when cartilage (the soft tissue in between the bones) in joints breaks down. This leads to bones rubbing against each other, which causes inflammation. Knee OA is caused by a number of things, such as aging, genetics, knee injuries, and repetitive stress on the knee joint. Symptoms of knee OA include pain, stiffness, swelling, difficulty bending the knee joint, and feeling the knee is unstable. While there is no cure for knee OA, there are various treatments available to help manage symptoms, improve knee joint function, and slow disease progress.
Weight plays an important role in managing knee OA. Excess body weight puts more strain on knee joints. Losing even a small amount of weight can lower the stress on your knees. Decreasing that stress can reduce inflammation, lessen pain, improve movement, and slow down further knee damage.

Frequently asked questions
If you qualify and decide to participate, you will receive:
- All study-related visits, assessments, and the study medicine at no cost
- Reimbursement for study-related expenses, such as parking and other transportation costs
- Guidance on diet and physical activity from a team of weight loss specialists, including a personalized plan
- Resources and education to help you continue a healthy lifestyle even after the clinical trial is completed
A placebo looks like the study medicine but does not have any active ingredients in it. It is used so that researchers can see if there are differences in how people respond to the study medicine.
Whether you are in the placebo group or the study medicine group, you will be making a difference in our understanding of how the study medicine works.
Because the study medicine affects digestion, some people may experience side effects like nausea, vomiting, diarrhea, and/or constipation. The study team can advise on ways to manage or minimize these types of side effects, such as eating smaller meals, drinking plenty of fluids, and eating only when hungry.
There are other common side effects that the study team will explain before you join the clinical trial.
The study team will work with you to develop a diet plan, including a reduced daily calorie intake goal, to help you lose weight in a healthy way.
They will also provide you with regular nutritional counseling to help you meet your weight loss goals.
You will be asked to complete at least 150 minutes of moderate exercise per week. A wide variety of resources will be available to help you plan your physical activities and keep you motivated.
Participation is completely voluntary. You can leave the clinical trial at any time and for any reason, without affecting your regular medical care or benefits.
References
- Atukorala I, Makovey J, Lawler L, et al. Is there a dose response relationship between weight loss and symptom improvement in persons with knee osteoarthritis? Arthritis Care Res. 2016;68(8):1106-1114. doi: 10.1002/acr.22805.
- Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012;64(4):465-474. doi:10.1002/acr.21596
- Messier SP, Mihalko SL, Legault C, et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: The IDEA Randomized Clinical Trial. JAMA. 2013;310(12):1263-1273. doi:10.1001/jama.2013.277669




